JAY WESLEY PETTEGREW
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD032305E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15213
Personal information
See more information about JAY WESLEY PETTEGREW at radaris.comName
Address
Phone
127 Elysian St, Pittsburgh, PA 15206
630 Linden Ave, Pittsburgh, PA 15208
3955 Bigelow St, Pittsburgh, PA 15213
127 Linshaw Ave, Pittsburgh, PA 15205
1261 Fairstead Ln, Pittsburgh, PA 15217
Professional information
Dr. Jay W Pettegrew, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Pediatric Neurology
Address:
260 Kappa Dr, Pittsburgh 15238
3811 Ohara St SUITE 1237-E, Pittsburgh 15213
(412) 624-1000 (Phone)
3811 Ohara St SUITE 1237-E, Pittsburgh 15213
(412) 624-1000 (Phone)
Certifications:
Neurology with Special Qualification in Child Neurology, 1977
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Illinois At Chicago / College of Medicine
Graduated: 1969
The Johns Hopkins Hospital
Barnes-Jewish Hospital
St Louis Chldns Hosp
University of Illinois At Chicago / College of Medicine
Graduated: 1969
The Johns Hopkins Hospital
Barnes-Jewish Hospital
St Louis Chldns Hosp
Jay Pettegrew, Pittsburgh PA
Work:
Western Psychiat
3811 Ohara St, Pittsburgh, PA 15261 University of Pittsburgh
130 Desoto St, Pittsburgh, PA 15213
3811 Ohara St, Pittsburgh, PA 15261 University of Pittsburgh
130 Desoto St, Pittsburgh, PA 15213
Compounds, Compositions And Methods For Medical Imaging Of Parkinson's Disease
US Patent:
8329142, Dec 11, 2012
Filed:
Jul 23, 2008
Appl. No.:
12/178281
Inventors:
Jay W. Pettegrew - Pittsburgh PA, US
Richard J. McClure - Pittsburgh PA, US
Kanagasabai Panchalingam - Monroeville PA, US
Richard J. McClure - Pittsburgh PA, US
Kanagasabai Panchalingam - Monroeville PA, US
International Classification:
A61K 51/00, A61M 36/14
US Classification:
424 189, 424 111, 424 165, 424 181, 424 185, 424 91
Abstract:
Compounds, compositions and methods for the detection and diagnosis of Parkinson's disease. Derivative lycerophosphocholine (GPC) compounds are used as a detection and diagnostic aid to measure progression of Parkinson's disease by detecting GPC binding to α-synuclein. Derivative CPG compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging (MRI) and/or positron emission tomography (PET) applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the detection, diagnosis and assessment of the progression of Parkinson's disease may be achieved.
Alkyl, Alkenyl And Alkynyl Chrysamine G Derivatives For Inhibition Of Cell Degeneration And Toxicity Associated With Amyloid Deposition
US Patent:
6133259, Oct 17, 2000
Filed:
Nov 9, 1998
Appl. No.:
9/188200
Inventors:
William E. Klunk - Pittsburgh PA
Jay W. Pettegrew - Pittsburgh PA
Chester A. Mathis - Pittsburgh PA
Jay W. Pettegrew - Pittsburgh PA
Chester A. Mathis - Pittsburgh PA
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
A61N 2528
US Classification:
5142305
Abstract:
Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
Compounds, Compositions And Methods For Medical Imaging Of Neuropsychiatric Disorders
US Patent:
7815894, Oct 19, 2010
Filed:
May 27, 2004
Appl. No.:
10/854894
Inventors:
Jay W. Pettegrew - Pittsburgh PA, US
Richard J. McClure - Pittsburgh PA, US
Kanagasabai Panchalingam - Monroeville PA, US
Billy W. Day - Pittsburgh PA, US
Richard J. McClure - Pittsburgh PA, US
Kanagasabai Panchalingam - Monroeville PA, US
Billy W. Day - Pittsburgh PA, US
International Classification:
A61K 51/00, A61M 36/14
US Classification:
424 177, 424 111, 424 165, 424 181, 424 185, 424 189, 424 91, 424 92, 424 93, 424 94
Abstract:
Compounds, compositions and methods for the diagnosis of Alzheimer's disease. Synthesized Glycerophosphocholine (GPC) may be used as a diagnostic aid to measure progression of Alzheimer's disease. GPC is a membrane phospholipid metabolite that is capable of binding specifically to the β-turn of beta amyloid (Aβ) peptide. Compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging and/or positron emission tomography applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the diagnosis and assessment of the progression of Alzheimer's disease may be achieved.
Alkyl, Alkenyl And Alkynyl Chrysamine G Derivatives For The Antemortem Diagnosis Of Alzheimer's Disease And In Vivo Imaging And Prevention Of Amyloid Deposition
US Patent:
6168776, Jan 2, 2001
Filed:
Apr 18, 1997
Appl. No.:
8/837494
Inventors:
William E. Klunk - Pittsburgh PA
Jay W. Pettegrew - Pittsburgh PA
Chester A. Mathis - Pittsburgh PA
Jay W. Pettegrew - Pittsburgh PA
Chester A. Mathis - Pittsburgh PA
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
A61K 4902, C07C 6233, C07C 6503, C07F 724
US Classification:
424 111
Abstract:
Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
Compound For The Antemortem Diagnosis Of Alzheimer's Disease And In Vivo Imaging And Prevention Of Amyloid Deposition
US Patent:
6114175, Sep 5, 2000
Filed:
Nov 9, 1998
Appl. No.:
9/188244
Inventors:
William E. Klunk - Pittsburgh PA
Jay W. Pettegrew - Pittsburgh PA
Chester A. Mathis - Pittsburgh PA
Jay W. Pettegrew - Pittsburgh PA
Chester A. Mathis - Pittsburgh PA
Assignee:
University of Pittsburgh - Pittsburgh PA
International Classification:
G01N 3348, A61M 3614
US Classification:
436 63
Abstract:
Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
Methor For Use Of Acetyl-L-Carnitine (Alcar) For Treatment Of Depressive Disorders In Humans
US Patent:
2005027, Dec 8, 2005
Filed:
Apr 27, 2005
Appl. No.:
11/117126
Inventors:
Jay Pettegrew - Pittsburgh PA, US
Samuel Gershon - Fox Chapel PA, US
Samuel Gershon - Fox Chapel PA, US
International Classification:
A61K031/22
US Classification:
514546000
Abstract:
Depression and bi-polar depression are treated with an acetyl-L-carnitine (ALCAR), thereby avoiding unwanted side-effects exhibited by conventional antidepressant agents. ALCAR also helps prevents recurrent episodes of depression and bi-polar depression and both provides beneficial membrane phospholipid and high-energy phosphate changes in a brain of human subjects with major depressive disorders (MDD).
Method And System For Diagnosis Of Neuropsychiatric Disorders Including Chronic Alcoholism
US Patent:
7700074, Apr 20, 2010
Filed:
Aug 23, 2005
Appl. No.:
11/209318
Inventors:
Jay W. Pettegrew - Pittsburgh PA, US
Kanagasabai Panchalingam - Monroeville PA, US
Kanagasabai Panchalingam - Monroeville PA, US
International Classification:
A61K 49/00, A61B 5/055, A61K 31/70, A61K 31/66, A61K 31/22, A61K 31/205
US Classification:
424 91, 424 93, 514 44, 514 75, 514546, 514556
Abstract:
Chronic alcoholism is a diverse and heterogeneous disorder that can be dichotomized into cognitively intact and cognitively impaired subgroups. At a molecular level, ethanol has been shown to have both acute and chronic effects on: Membrane biophysical properties, Membrane composition and metabolism, Protein phosphorylation, Lipid metabolic signaling, Lipoprotein transport of cholesterol. Actual molecular underpinnings are determined for cognitive impairment seen in some chronic alcoholism subjects including molecular/metabolic alterations of phospholipid and ganglioside metabolisms.
Carnitine In The Treatment Of Depression
US Patent:
2004000, Jan 15, 2004
Filed:
Feb 7, 2003
Appl. No.:
10/359560
Inventors:
Jay Pettegrew - Pittsburgh PA, US
Samuel Gershon - Fox Chapel PA, US
Samuel Gershon - Fox Chapel PA, US
Assignee:
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
International Classification:
A61K031/7024, A61K031/22, A61K031/66
US Classification:
514/023000, 514/550000, 514/129000
Abstract:
Geriatric depression is treated with L-carnitine or an alkanoyl L-carnitine, desirably acetyl L-carnitine thereby avoiding unwanted side-effects exhibited by conventional antidepressant agents.